It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG in pheochromocytoma and paraganglioma.
‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial’ (PRESENTATION NUMBER: OR04-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What is the rationale for the use of Iodine-131 (I-131)-labeled metaiodobenzylguanidine (MIBG) in pheochromocytoma and paraganglioma? (0:21)
- What has the recent Phase II study taught us about the efficacy and safety of I-131 MIBG? (4:11)
- Could you tell us a little about the tumour biomarker analysis and its findings? (7:51)
Disclosures: Professor Camilo Jimenez is a principal investigator of phase 2 and phase 4 clinical trials with high specific activity MIBG for patients with metastatic pheochromocytomas and paragangliomas and has received research support from Lantheus Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ENDO 2021 (Virtual).
